- Home
- KMT vs IMCR Comparison
KMT vs IMCR Comparison
Compare KMT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMT
- IMCR
- Stock Information
- Founded
- KMT 1938
- IMCR 2008
- Country
- KMT United States
- IMCR United Kingdom
- Employees
- KMT N/A
- IMCR N/A
- Industry
- KMT Industrial Machinery/Components
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KMT Industrials
- IMCR Health Care
- Exchange
- KMT Nasdaq
- IMCR Nasdaq
- Market Cap
- KMT 1.7B
- IMCR 1.4B
- IPO Year
- KMT N/A
- IMCR 2021
- Fundamental
- Price
- KMT $21.62
- IMCR $29.58
- Analyst Decision
- KMT Hold
- IMCR Buy
- Analyst Count
- KMT 5
- IMCR 12
- Target Price
- KMT $26.40
- IMCR $63.00
- AVG Volume (30 Days)
- KMT 1.0M
- IMCR 372.8K
- Earning Date
- KMT 05-07-2025
- IMCR 05-07-2025
- Dividend Yield
- KMT 3.70%
- IMCR N/A
- EPS Growth
- KMT N/A
- IMCR N/A
- EPS
- KMT 1.22
- IMCR N/A
- Revenue
- KMT $2,023,102,000.00
- IMCR $310,202,000.00
- Revenue This Year
- KMT N/A
- IMCR $18.97
- Revenue Next Year
- KMT $1.91
- IMCR $8.43
- P/E Ratio
- KMT $17.70
- IMCR N/A
- Revenue Growth
- KMT N/A
- IMCR 24.36
- 52 Week Low
- KMT $20.50
- IMCR $27.19
- 52 Week High
- KMT $32.18
- IMCR $66.00
- Technical
- Relative Strength Index (RSI)
- KMT 44.64
- IMCR 49.95
- Support Level
- KMT $21.30
- IMCR $28.92
- Resistance Level
- KMT $22.72
- IMCR $30.04
- Average True Range (ATR)
- KMT 0.56
- IMCR 1.49
- MACD
- KMT 0.10
- IMCR 0.10
- Stochastic Oscillator
- KMT 39.23
- IMCR 53.71
About KMT Kennametal Inc.
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.